SCHEMBL2905684

SCHEMBL2905684

COc1ccc(OC)c(C(=O)C=O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.67
MAPT P10636 2/20 0.67
NPSR1 Q6W5P4 2/20 0.67
HTT P42858 1/20 0.67
PDE4A P27815 2/20 0.61
PDE4B Q07343 2/20 0.61
PDE4C Q08493 2/20 0.61
PDE4D Q08499 2/20 0.61
ALDH1A1 P00352 1/20 0.59
POLB P06746 1/20 0.58
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
ATM Q13315 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPC1 O15118 1/20 0.51
CYP2C9 P11712 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31167603 0.87 ABCG2 (0.79) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL6350154 0.86 ABCG2 (0.67) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL24163300 0.83 ABCG2 (0.72) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL8426128 0.82 MAPT (0.49) ABCG2MAPTNPSR1HTTALDH1A1
SCHEMBL11095055 0.81 ABCG2 (0.70) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL11094331 0.81 ABCG2 (0.70) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL12228747 0.81 MAPT (0.82) ABCG2MAPTNPSR1HTTPDE4A
SCHEMBL21668146 0.81 TYK2 (0.51) ABCG2MAPTNPSR1HTTALDH1A1
Water SCHEMBL9265170 0.81 MAPT (0.47) ABCG2MAPTNPSR1HTTALDH1A1
SCHEMBL30513967 0.81 TYK2 (0.51) ABCG2MAPTNPSR1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013018626-A1 METHOD FOR PRODUCING ALPHA-KETOALDEHYDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-07 WO disclosed
EP-1546083-B1 NOVEL SUBSTITUTED ARYLHEXADIENOIC ACIDS AND ESTERS THEREOF WHICH CAN BE USED FOR THE TREATMENT AND PREVENTION OF DIABETES, DYSLIPIDAEMIA AND ATHEROSCLEROSIS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THE PREPARATION OF THEM MERCK PATENT GMBH (DE) 2010-08-11 EP disclosed
US-7737176-B2 Substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them MERCK PATENT GMBH (DE) 2010-06-15 US disclosed
US-20060052447-A1 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositios comprising them and processes for the preparation of them MERCK PATENT GMBH (DE) 2006-03-09 US disclosed
EP-1546083-A1 NOVEL SUBSTITUTED ARYLHEXADIENOIC ACIDS AND ESTERS THEREOF WHICH CAN BE USED FOR THE TREATMENT AND PREVENTION OF DIABETES, DYSLIPIDAEMIA AND ATHEROSCLEROSIS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THE PREPARATION OF THEM MERCK PATENT GmbH (DE) 2005-06-29 EP disclosed
WO-2004031116-A1 NOVEL SUBSTITUTED ARYLHEXADIENOIC ACIDS AND ESTERS THEREOF WHICH CAN BE USED FOR THE TREATMENT AND PREVENTION OF DIABETES, DYSLIPIDAEMIA AND ATHEROSCLEROSIS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THE PREPARATION OF THEM MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052447-A1 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositios comprising them and processes for the preparation of them CYP46A1, DHCR7, ALOX15B ABCG2 572/4885MAPT 4126/4885NPSR1 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.